Ancestry and frequency of genetic variants in the general population are confounders in the characterization of germline variants linked to cancer.
Butyrophilins
/ genetics
Cell Adhesion Molecules, Neuronal
/ genetics
DNA Copy Number Variations
/ genetics
Databases, Genetic
Disease-Free Survival
Female
GPI-Linked Proteins
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Genetic Predisposition to Disease
Genome-Wide Association Study
Germ-Line Mutation
/ genetics
Glioma
/ genetics
Humans
Kaplan-Meier Estimate
Male
Pediatrics
Polymorphism, Single Nucleotide
/ genetics
Exome Sequencing
Whole Genome Sequencing
Germline variants
Pediatric high-grade glioma
Single-cell RNA-seq
Whole-genome sequencing
Journal
BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552
Informations de publication
Date de publication:
06 05 2020
06 05 2020
Historique:
received:
11
02
2020
accepted:
23
04
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
17
7
2020
Statut:
epublish
Résumé
Pediatric high-grade gliomas (pHGGs) are incurable malignant brain cancers. Clear somatic genetic drivers are difficult to identify in the majority of cases. We hypothesized that this may be due to the existence of germline variants that influence tumor etiology and/or progression and are filtered out using traditional pipelines for somatic mutation calling. In this study, we analyzed whole-genome sequencing (WGS) datasets of matched germlines and tumor tissues to identify recurrent germline variants in pHGG patients. We identified two structural variants that were highly recurrent in a discovery cohort of 8 pHGG patients. One was a ~ 40 kb deletion immediately upstream of the NEGR1 locus and predicted to remove the promoter region of this gene. This copy number variant (CNV) was present in all patients in our discovery cohort (n = 8) and in 86.3% of patients in our validation cohort (n = 73 cases). We also identified a second recurrent deletion 55.7 kb in size affecting the BTNL3 and BTNL8 loci. This BTNL3-8 deletion was observed in 62.5% patients in our discovery cohort, and in 17.8% of the patients in the validation cohort. Our single-cell RNA sequencing (scRNA-seq) data showed that both deletions result in disruption of transcription of the affected genes. However, analysis of genomic information from multiple non-cancer cohorts showed that both the NEGR1 promoter deletion and the BTNL3-8 deletion were CNVs occurring at high frequencies in the general population. Intriguingly, the upstream NEGR1 CNV deletion was homozygous in ~ 40% of individuals in the non-cancer population. This finding was immediately relevant because the affected genes have important physiological functions, and our analyses showed that NEGR1 expression levels have prognostic value for pHGG patient survival. We also found that these deletions occurred at different frequencies among different ethnic groups. Our study highlights the need to integrate cancer genomic analyses and genomic data from large control populations. Failure to do so may lead to spurious association of genes with cancer etiology. Importantly, our results showcase the need for careful evaluation of differences in the frequency of genetic variants among different ethnic groups.
Sections du résumé
BACKGROUND
Pediatric high-grade gliomas (pHGGs) are incurable malignant brain cancers. Clear somatic genetic drivers are difficult to identify in the majority of cases. We hypothesized that this may be due to the existence of germline variants that influence tumor etiology and/or progression and are filtered out using traditional pipelines for somatic mutation calling.
METHODS
In this study, we analyzed whole-genome sequencing (WGS) datasets of matched germlines and tumor tissues to identify recurrent germline variants in pHGG patients.
RESULTS
We identified two structural variants that were highly recurrent in a discovery cohort of 8 pHGG patients. One was a ~ 40 kb deletion immediately upstream of the NEGR1 locus and predicted to remove the promoter region of this gene. This copy number variant (CNV) was present in all patients in our discovery cohort (n = 8) and in 86.3% of patients in our validation cohort (n = 73 cases). We also identified a second recurrent deletion 55.7 kb in size affecting the BTNL3 and BTNL8 loci. This BTNL3-8 deletion was observed in 62.5% patients in our discovery cohort, and in 17.8% of the patients in the validation cohort. Our single-cell RNA sequencing (scRNA-seq) data showed that both deletions result in disruption of transcription of the affected genes. However, analysis of genomic information from multiple non-cancer cohorts showed that both the NEGR1 promoter deletion and the BTNL3-8 deletion were CNVs occurring at high frequencies in the general population. Intriguingly, the upstream NEGR1 CNV deletion was homozygous in ~ 40% of individuals in the non-cancer population. This finding was immediately relevant because the affected genes have important physiological functions, and our analyses showed that NEGR1 expression levels have prognostic value for pHGG patient survival. We also found that these deletions occurred at different frequencies among different ethnic groups.
CONCLUSIONS
Our study highlights the need to integrate cancer genomic analyses and genomic data from large control populations. Failure to do so may lead to spurious association of genes with cancer etiology. Importantly, our results showcase the need for careful evaluation of differences in the frequency of genetic variants among different ethnic groups.
Identifiants
pubmed: 32375678
doi: 10.1186/s12881-020-01033-x
pii: 10.1186/s12881-020-01033-x
pmc: PMC7201963
doi:
Substances chimiques
BTNL8 protein, human
0
Butyrophilins
0
Cell Adhesion Molecules, Neuronal
0
GPI-Linked Proteins
0
NEGR1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Subventions
Organisme : CIHR
ID : ICT-156651
Pays : Canada
Références
Brain. 2018 Sep 1;141(9):2772-2794
pubmed: 30059965
Acta Neuropathol Commun. 2017 Oct 30;5(1):78
pubmed: 29084603
NCHS Data Brief. 2016 Sep;(257):1-8
pubmed: 27648773
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Cancer Res. 2019 May 1;79(9):2111-2123
pubmed: 30877103
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Acta Neuropathol. 2012 Sep;124(3):439-47
pubmed: 22661320
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Mol Immunol. 2013 Dec;56(4):819-28
pubmed: 24036152
CMAJ. 2018 Feb 5;190(5):E126-E136
pubmed: 29431110
Nat Rev Genet. 2015 Mar;16(3):172-83
pubmed: 25645873
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
Cancer Cell. 2018 May 14;33(5):829-842.e5
pubmed: 29763623
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Nat Methods. 2017 Oct;14(10):955-958
pubmed: 28846088
Cancer Sci. 2011 Sep;102(9):1645-50
pubmed: 21624008
Front Mol Neurosci. 2018 Feb 09;11:30
pubmed: 29479305
Nat Neurosci. 2017 Apr;20(4):602-611
pubmed: 28263302
J Clin Oncol. 2010 Jun 20;28(18):3061-8
pubmed: 20479398
Cancer Cell. 2019 Jan 14;35(1):140-155.e7
pubmed: 30595505
Childs Nerv Syst. 2010 Aug;26(8):1035-41
pubmed: 20217098
Clin Cancer Res. 2013 Mar 1;19(5):1021-34
pubmed: 23460533
Nucleic Acids Res. 2014 Jan;42(Database issue):D986-92
pubmed: 24174537
Cell. 2019 Mar 21;177(1):26-31
pubmed: 30901543
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Neuro Oncol. 2011 Mar;13(3):317-23
pubmed: 21339192
Cancer Cell. 2017 Nov 13;32(5):684-700.e9
pubmed: 29107533
Immun Inflamm Dis. 2016 Apr 01;4(2):191-200
pubmed: 27957327
J Cancer. 2014 Jul 21;5(7):598-608
pubmed: 25057311
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Nat Med. 2018 Aug;24(8):1204-1215
pubmed: 29967352